FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2762465308> ?p ?o ?g. }

• W2762465308 endingPage "v363" @default.
• W2762465308 startingPage "v363" @default.
• W2762465308 abstract "Background: Cell therapy with TIL is an effective treatment with acceptable safety profile for advanced metastatic melanoma patients. TIL products can be centrally manufactured for broad clinical application. Adoptive cell therapy with TIL involves collection of autologous lymphocytes from the tumor via surgical resection, ex vivo expansion of TIL, lymphodepletion of the patient prior to infusion of TIL, followed by infusion of TIL and treatment with IL-2. Here, we present findings related to expanding TIL directly from lymphoma. Methods: Using methods for TIL isolation and growth developed at Lion, we expanded TIL from 5/5 lymphoma (1 MCL, 3 follicular, 1 DLBCL) with Interleukin 2 for 11-14 days and subsequent rapid expansion for 14 days using mitogenic anti-CD3 antibody and irradiated allogeneic PBMC. Results: TIL were generated from all 5 lymphoma tumors with a maximum expansion index of 680-fold, significantly higher than previously reported. Mean CD3+ T cell population was 95% (vs 75% previously reported). As with TIL expansion from melanoma, we observed a marked relative increase in effector memory cells in lymphoma TIL. A significant increase in TEMRA (p = 0.0013; CD4, CD8) and CD28+CD4 + (p = 0.008) subsets was observed in lymphoma compared with melanoma TIL cultures. Bioluminescent Redirected Lysis Assay (BRLA) to assess TIL cytolytic activity at 4 hrs ranged from <1-6 LU50 in lymphoma TIL compared to melanoma TIL (11-75 LU50, 4hrs). ELISpot and ELISA analysis revealed IFN-γ production by lymphoma TIL comparable to that of melanoma TIL. Consistent with the observation that lymphoma-reactive T-cells are primarily TH2 and TH17, nanostring analysis revealed that lymphoma TIL expressed higher levels of RORC and IL17A than melanoma TIL. Conclusions: We demonstrate here the feasibility of growing TIL from lymphoma that have effector functions comparable to that of melanoma TIL. These findings serve as a rationale for considering TIL cell therapy for patients with lymphoma. Legal entity responsible for the study: Lion Biotechnologies, Inc Funding: Lion Biotechnologies Inc Disclosure: L. Karyampudi, A. Gokuldass, M. Blaskovich, M.T. Lotze: Employee of Lion Biotechnologies, Inc, receive compensation from Lion. Hold stock and/or stock options in Lion Biotechnologies, Inc. M. Fardis: Employee and director of Lion Biotechnologies, Inc, receive compensation from Lion. Hold stock and/or stock options in Lion Biotechnologies, Inc. Member of the Board of Directors of Lion Biotechnologies, Inc." @default.
• W2762465308 created "2017-10-20" @default.
• W2762465308 creator A5036474702 @default.
• W2762465308 creator A5046086752 @default.
• W2762465308 creator A5051567432 @default.
• W2762465308 creator A5052543382 @default.
• W2762465308 creator A5053542607 @default.
• W2762465308 date "2017-09-01" @default.
• W2762465308 modified "2023-10-18" @default.
• W2762465308 title "Phenotypic and functional characterization of tumor infiltrating lymphocytes (TIL) grown from non-hodgkin lymphoma tumors: Implications for the development of novel therapies for lymphoma" @default.
• W2762465308 doi "https://doi.org/10.1093/annonc/mdx373.023" @default.
• W2762465308 hasPublicationYear "2017" @default.
• W2762465308 type Work @default.
• W2762465308 sameAs 2762465308 @default.
• W2762465308 citedByCount "1" @default.
• W2762465308 countsByYear W27624653082022 @default.
• W2762465308 crossrefType "journal-article" @default.
• W2762465308 hasAuthorship W2762465308A5036474702 @default.
• W2762465308 hasAuthorship W2762465308A5046086752 @default.
• W2762465308 hasAuthorship W2762465308A5051567432 @default.
• W2762465308 hasAuthorship W2762465308A5052543382 @default.
• W2762465308 hasAuthorship W2762465308A5053542607 @default.
• W2762465308 hasBestOaLocation W27624653081 @default.
• W2762465308 hasConcept C167672396 @default.
• W2762465308 hasConcept C203014093 @default.
• W2762465308 hasConcept C2777058707 @default.
• W2762465308 hasConcept C2777658100 @default.
• W2762465308 hasConcept C2778326572 @default.
• W2762465308 hasConcept C2779053233 @default.
• W2762465308 hasConcept C2779338263 @default.
• W2762465308 hasConcept C502942594 @default.
• W2762465308 hasConcept C71924100 @default.
• W2762465308 hasConcept C8891405 @default.
• W2762465308 hasConceptScore W2762465308C167672396 @default.
• W2762465308 hasConceptScore W2762465308C203014093 @default.
• W2762465308 hasConceptScore W2762465308C2777058707 @default.
• W2762465308 hasConceptScore W2762465308C2777658100 @default.
• W2762465308 hasConceptScore W2762465308C2778326572 @default.
• W2762465308 hasConceptScore W2762465308C2779053233 @default.
• W2762465308 hasConceptScore W2762465308C2779338263 @default.
• W2762465308 hasConceptScore W2762465308C502942594 @default.
• W2762465308 hasConceptScore W2762465308C71924100 @default.
• W2762465308 hasConceptScore W2762465308C8891405 @default.
• W2762465308 hasLocation W27624653081 @default.
• W2762465308 hasOpenAccess W2762465308 @default.
• W2762465308 hasPrimaryLocation W27624653081 @default.
• W2762465308 hasRelatedWork W1484524519 @default.
• W2762465308 hasRelatedWork W1501529729 @default.
• W2762465308 hasRelatedWork W1970289093 @default.
• W2762465308 hasRelatedWork W2058428031 @default.
• W2762465308 hasRelatedWork W2166919567 @default.
• W2762465308 hasRelatedWork W2399536512 @default.
• W2762465308 hasRelatedWork W3038845400 @default.
• W2762465308 hasRelatedWork W3104483115 @default.
• W2762465308 hasRelatedWork W4318589268 @default.
• W2762465308 hasRelatedWork W6572435 @default.
• W2762465308 hasVolume "28" @default.
• W2762465308 isParatext "false" @default.
• W2762465308 isRetracted "false" @default.
• W2762465308 magId "2762465308" @default.
• W2762465308 workType "article" @default.